Aevitas Therapeutics Inc., a Fortress Biotech Inc. partner company focused on the development of novel gene therapy approaches for complement-mediated diseases, has appointed Markus Peters, Ph.D., M.Sc., as president and chief executive officer.   Peters was most recently the chief operating officer of Gemini Therapeutics after serving as the chief commercial officer of Agilis Biotherapeutics. Peters will lead the company as it advances its proprietary platform designed to deliver engineered, fu...